Metformin suppresses oxidative phosphorylation in OPCs but enhances it in oligodendrocytes, despite both expressing AMPK. The mechanistic basis for this cell-type-specific metabolic switching is unexplained but critical for understanding therapeutic targeting. Gap type: unexplained_observation Source paper: The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation. (2023, Frontiers in cellular neuroscience, PMID:37904733)
Landscape Summary: What molecular mechanisms explain metformin's opposite metabolic effects on OPCs versus oligodendrocytes? is a 0.82 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What molecular mechanisms explain metformin's opposite metabolic effects on OPCs versus oligodendrocytes? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: